Entrada Therapeutics
TRDA
55 hedge funds and large institutions have $411M invested in Entrada Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 5 closing their positions.
236% more capital inflows, than outflows
Capital inflows: $6.41M | Capital outflows: $1.91M
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
0.69% more ownership
Funds ownership: 77.57% → 78.26% (+0.69%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less funds holding
Funds holding: 56 → 55 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$1.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$972K |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$939K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$598K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$412K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$434K |
| 2 |
Millennium Management
New York
|
-$277K |
| 3 |
Man Group
London,
United Kingdom
|
-$219K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$171K |
| 5 |
Morgan Stanley
New York
|
-$141K |
TRDA Hedge Fund Activity: Q3 2023 in Review
55 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2023, worth a combined $411M — up 5.5% from $390M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRDA and 4 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 19 added.
The largest buyer was American Century Companies, adding an estimated $1.8M. The largest seller was Redmile Group, cutting an estimated $434K.
- 55 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2023, down from 56 in Q2 2023.
- Funds reported $411M of Entrada Therapeutics stock for Q3 2023, up 5.5% quarter-over-quarter.
- 4 funds opened new Entrada Therapeutics positions in Q3 2023 and 5 closed out, a net change of -1 holder.
- The largest Entrada Therapeutics buyer in Q3 2023 was American Century Companies, an estimated $1.8M added.
- The largest Entrada Therapeutics seller in Q3 2023 was Redmile Group, an estimated $434K sold.
Based on aggregated 13F filings for Q3 2023.